0001246360-19-000766.txt : 20190225
0001246360-19-000766.hdr.sgml : 20190225
20190225175611
ACCESSION NUMBER: 0001246360-19-000766
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190221
FILED AS OF DATE: 20190225
DATE AS OF CHANGE: 20190225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TOWSE MATTHEW W
CENTRAL INDEX KEY: 0001195852
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51567
FILM NUMBER: 19630853
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NxStage Medical, Inc.
CENTRAL INDEX KEY: 0001333170
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 043454702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 MERRIMACK STREET
CITY: LAWRENCE
STATE: MA
ZIP: 01843
BUSINESS PHONE: 978-687-4700
MAIL ADDRESS:
STREET 1: 350 MERRIMACK STREET
CITY: LAWRENCE
STATE: MA
ZIP: 01843
4
1
form.xml
PRIMARY DOCUMENT
X0306
4
2019-02-21
true
0001333170
NxStage Medical, Inc.
NXTM
0001195852
TOWSE MATTHEW W
350 MERRIMACK STREET
LAWRENCE
MA
01843
false
true
false
false
SVP and Chief Financial Office
Common Stock
2019-02-21
4
D
false
28396
30
D
0
D
Stock Option (Right to Buy)
14.66
2019-02-21
4
D
false
60958
0
D
2014-04-10
2024-03-09
Common Stock
60958
0
D
Stock Option (Right to Buy)
16.66
2019-02-21
4
D
false
65618
0
D
2015-04-03
2025-03-02
Common Stock
65618
0
D
Stock Option (Right to Buy)
15.58
2019-02-21
4
D
false
89386
0
D
2016-04-09
2026-03-08
Common Stock
89386
0
D
Stock Option (Right to Buy)
27.89
2019-02-21
4
D
false
49855
0
D
2017-04-09
2027-03-08
Common Stock
49855
0
D
Restricted Stock Unit
0
2019-02-21
4
D
false
11643
0
D
2018-03-09
2020-03-09
Common Stock
11643
0
D
Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share.
/s/ Aras Lapinskas, attorney-in-fact for Matthew Towse
2019-02-25